| Crosstalk between cannabinoid receptor 2 and lysophosphatidic acid receptor 5. | Crosstalk between cannabinoid receptor 2 and lysophosphatidic acid receptor 5.
Song E, Ghil S. | 06/3/2023 |
| Emerging roles of lysophosphatidic acid receptor subtype 5 (LPAR5) in inflammatory diseases and cancer. | Emerging roles of lysophosphatidic acid receptor subtype 5 (LPAR5) in inflammatory diseases and cancer.
Dacheux MA, Norman DD, Tigyi GJ, Lee SC., Free PMC Article | 05/8/2023 |
| Potential role of LPAR5 gene in prognosis and immunity of thyroid papillary carcinoma and pan-cancer. | Potential role of LPAR5 gene in prognosis and immunity of thyroid papillary carcinoma and pan-cancer.
Zhang B, Zhang L, Qi P, Pang R, Wang Z, Liu X, Shi Q, Zhang Q., Free PMC Article | 04/12/2023 |
| Infiltration of LPAR5[+] macrophages in osteosarcoma tumor microenvironment predicts better outcomes. | Infiltration of LPAR5(+) macrophages in osteosarcoma tumor microenvironment predicts better outcomes.
He Y, Zhou H, Huang X, Qu Y, Wang Y, Pei W, Zhang R, Chen S, You H., Free PMC Article | 01/14/2023 |
| LPAR5 confers radioresistance to cancer cells associated with EMT activation via the ERK/Snail pathway. | LPAR5 confers radioresistance to cancer cells associated with EMT activation via the ERK/Snail pathway.
Sun XY, Li HZ, Xie DF, Gao SS, Huang X, Guan H, Bai CJ, Zhou PK., Free PMC Article | 10/15/2022 |
| Control of Intestinal Epithelial Permeability by Lysophosphatidic Acid Receptor 5. | Control of Intestinal Epithelial Permeability by Lysophosphatidic Acid Receptor 5.
Wang M, He P, Han Y, Dong L, Yun CC., Free PMC Article | 03/12/2022 |
| Lysophosphatidic acid mediates the pathogenesis of psoriasis by activating keratinocytes through LPAR5. | Lysophosphatidic acid mediates the pathogenesis of psoriasis by activating keratinocytes through LPAR5.
Lei L, Yan B, Liu P, Li J, Chen C, Zhu W, Kuang Y, Chen X, Peng C., Free PMC Article | 03/5/2022 |
| Interference with lysophosphatidic acid receptor 5 ameliorates oxidized low-density lipoprotein-induced human umbilical vein endothelial cell injury by inactivating NOD-like receptor family, pyrin domain containing 3 inflammasome signaling. | Interference with lysophosphatidic acid receptor 5 ameliorates oxidized low-density lipoprotein-induced human umbilical vein endothelial cell injury by inactivating NOD-like receptor family, pyrin domain containing 3 inflammasome signaling.
Xu L, Xu C, Lin X, Lu H, Cai Y., Free PMC Article | 02/19/2022 |
| LPAR5 stimulates the malignant progression of non-small-cell lung carcinoma by upregulating MLLT11. | LPAR5 stimulates the malignant progression of non-small-cell lung carcinoma by upregulating MLLT11.
Zhang HP, Chen QK, Xu JF. | 05/22/2021 |
| LPAR5 promotes thyroid carcinoma cell proliferation and migration by activating class IA PI3K catalytic subunit p110beta. | LPAR5 promotes thyroid carcinoma cell proliferation and migration by activating class IA PI3K catalytic subunit p110β.
Zhao WJ, Zhu LL, Yang WQ, Xu SJ, Chen J, Ding XF, Liang Y, Chen G., Free PMC Article | 04/13/2021 |
| Lysophosphatidic acid receptor 5 transactivation of TGFBR1 stimulates the mRNA expression of proteoglycan synthesizing genes XYLT1 and CHST3. | Lysophosphatidic acid receptor 5 transactivation of TGFBR1 stimulates the mRNA expression of proteoglycan synthesizing genes XYLT1 and CHST3.
Zhou Y, Little PJ, Cao Y, Ta HT, Kamato D. | 01/9/2021 |
| LPA5 Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling. | LPA(5) Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling.
Mathew D, Kremer KN, Strauch P, Tigyi G, Pelanda R, Torres RM., Free PMC Article | 08/22/2020 |
| LPAR5 expression was elevated in A375cells treated with anticancer drugs. The high cell survival of highly migratory A375cells is associated with the low LPAR5 expression. The cell survival of A375cells treated with anticancer drugs was increased by LPA5 knockdown. | Modulation of chemoresistance by lysophosphatidic acid (LPA) signaling through LPA(5) in melanoma cells treated with anticancer drugs.
Minami K, Ueda N, Maeda H, Ishimoto K, Otagaki S, Tsujiuchi T. | 06/13/2020 |
| Downregulation of LPAR5 expression can inhibit the physiological process of PTC, and this phenomenon is related to the PI3K/AKT pathway and EMT. | Lysophosphatidic Acid Receptor 5 (LPAR5) Plays a Significance Role in Papillary Thyroid Cancer via Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin (mTOR) Pathway.
Wu CY, Zheng C, Xia EJ, Quan RD, Hu J, Zhang XH, Hao RT., Free PMC Article | 06/6/2020 |
| LPAR2 and LPAR5 regulate cellular functions during tumor progression in fibrosarcoma HT1080 cells. | Lysophosphatidic acid receptor-2 (LPA(2)) and LPA(5) regulate cellular functions during tumor progression in fibrosarcoma HT1080 cells.
Takahashi K, Minami K, Otagaki S, Ishimoto K, Fukushima K, Fukushima N, Honoki K, Tsujiuchi T. | 01/5/2019 |
| It signaling may play a key role in the mechanisms underlying neuropathic pain following demyelination in the brain. | LPA5 signaling is involved in multiple sclerosis-mediated neuropathic pain in the cuprizone mouse model.
Tsukahara R, Yamamoto S, Yoshikawa K, Gotoh M, Tsukahara T, Neyama H, Ishii S, Akahoshi N, Yanagida K, Sumida H, Araki M, Araki K, Yamamura KI, Murakami-Murofushi K, Ueda H. | 04/28/2018 |
| These results suggest that the cell motile activity is regulated through the induction of LPA5 by phorbol ester and anticancer drug treatments in A375cells. | Involvement of LPA receptor-5 in the enhancement of cell motile activity by phorbol ester and anticancer drug treatments in melanoma A375 cells.
Fukushima K, Takahashi K, Kurokawa A, Ishimoto K, Otagaki S, Minami K, Fukushima N, Honoki K, Tsujiuchi T. | 02/17/2018 |
| These results suggest that the diverse roles of LPA4, LPA5 and LPA6 are involved in the activation of tumor progression in pancreatic cancer cells. | Diverse effects of LPA4, LPA5 and LPA6 on the activation of tumor progression in pancreatic cancer cells.
Ishii S, Hirane M, Fukushima K, Tomimatsu A, Fukushima N, Tsujiuchi T. | 07/25/2015 |
| Down-regulation of LPA receptor 5 contributes to aberrant LPA signalling in EBV-associated nasopharyngeal carcinoma. | Down-regulation of LPA receptor 5 contributes to aberrant LPA signalling in EBV-associated nasopharyngeal carcinoma.
Yap LF, Velapasamy S, Lee HM, Thavaraj S, Rajadurai P, Wei W, Vrzalikova K, Ibrahim MH, Khoo AS, Tsao SW, Paterson IC, Taylor GS, Dawson CW, Murray PG. | 03/21/2015 |
| MMP-2 and MMP-9 were found in HT1080L5 cells, in comparison with control cells. These results suggest that LPA signaling via LPA5 negatively regulates the cell motile and invasive activities of human sarcoma cells. | Lysophosphatidic acid receptor-5 negatively regulates cell motile and invasive activities of human sarcoma cell lines.
Dong Y, Hirane M, Araki M, Fukushima N, Honoki K, Tsujiuchi T. | 02/14/2015 |
| These results suggest that LPA5 may act as a negative regulator of cellular responses in mouse fibroblast 3T3 cells, similar to the case for LPA1. | Lysophosphatidic acid receptor-5 negatively regulates cellular responses in mouse fibroblast 3T3 cells.
Dong Y, Hirane M, Araki M, Fukushima N, Tsujiuchi T. | 05/24/2014 |
| It was shown that lysophosphatidic acid 5 receptor transactivated the epidermal growth factor receptor and that inhibition of epidermal growth factor receptor blocked lysophosphatidic acid 5 receptor-dependent activation of NHE3. | Lysophosphatidic acid 5 receptor induces activation of Na(+)/H(+) exchanger 3 via apical epidermal growth factor receptor in intestinal epithelial cells.
Yoo BK, He P, Lee SJ, Yun CC., Free PMC Article | 12/31/2011 |
| LPA5 is a bona fide LPA receptor on human mast cells responsible for the majority of LPA induced MIP-1beta release. | LPA5 is abundantly expressed by human mast cells and important for lysophosphatidic acid induced MIP-1β release.
Lundequist A, Boyce JA., Free PMC Article | 07/23/2011 |
| LPA4 and LPA5 receptors induce osteoblastic differentiation of human mesenchymal stem cells | LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4.
Liu YB, Kharode Y, Bodine PV, Yaworsky PJ, Robinson JA, Billiard J. | 08/16/2010 |
| Data show that CLL cells express LPA receptors LPA(1-5) and VEGF receptors, and the plasma levels of VEGF are elevated in CLL patients. | Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression.
Kumar SA, Hu X, Brown M, Kuschak B, Hernandez TA, Johnston JB, Gibson SB. | 03/29/2010 |